Every material Form 8-K IRIDEX CORP has filed with the SEC since July 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
IRIDEX received a Nasdaq notice on August 27, 2026 saying its stock had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until February 23, 2027 to regain compliance, and the filing says the notice has no immediate effect on the stock's listing or trading.
Nasdaq notice received August 27, 2026 for the $1.00 minimum bid price requirement on the Nasdaq Capital Market
Cure period runs 180 calendar days to February 23, 2027; compliance requires a closing bid of at least $1.00 for 10 consecutive business days
If not cured, the company may qualify for a second 180-day period, which may require a reverse stock split; otherwise delisting proceedings and an appeal right would follow
Iridex reported second-quarter 2026 revenue of $12.6 million, down 7% from a year earlier, as lower retina sales outweighed growth in its Cyclo G6 glaucoma products. The net loss widened to $1.3 million, or $0.07 per share, from $1.0 million, or $0.06 per share, and the company reaffirmed its full-year 2026 revenue guidance of $51 million to $53 million.
Total revenue was $12.6 million, compared with $13.6 million in the prior-year quarter; retina product revenue fell to $6.5 million from $8.0 million.
Cyclo G6 product family revenue rose 19% to $3.9 million, with 17,700 probes sold versus 13,100 a year earlier.
Net loss was $1.3 million, or $0.07 per share, versus $1.0 million, or $0.06 per share, in the second quarter of 2025.
Full-year 2026 revenue guidance of $51 million to $53 million was reaffirmed; adjusted operating expense guidance is $19 million to $19.5 million.
IRIDEX's annual meeting reconvened on July 10, 2026, after a June 12 adjournment, and all five director nominees were elected. The board says the vote results, which showed large withhold votes for directors Scott Shuda and Beverly Huss, are the product of a stealth proxy campaign involving at least one director, and it describes possible violations of fiduciary and federal securities rules.
Shuda and Huss each drew more withhold votes than for votes: 7,518,539 withheld versus 5,656,948 for (Shuda) and 7,436,354 withheld versus 5,739,133 for (Huss)
Stockholders ratified BPM LLP as auditor for the fiscal year ending January 2, 2027, with 16,675,096 votes for
The board says the campaign may have created an undisclosed group in violation of SEC Rule 13D and that its investigation is ongoing, with dispute involving Novel Inspiration International Co., Ltd., a Series B Preferred holder
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every IRIDEX CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →